2. Search Result
Search Result
Results for "

138470-70-9

" in MedChemExpress (MCE) Product Catalog:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-123593
    Mozavaptan hydrochloride
    1 Publications Verification

    OPC-31260 hydrochloride

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride
  • HY-123593R
    Mozavaptan hydrochloride (Standard)

    OPC-31260 hydrochloride (Standard)

    		 Vasopressin Receptor Reference Standards Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride). This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan hydrochloride (Standard)
  • HY-18346
    Mozavaptan
    1 Publications Verification

    OPC-31260

    		 Vasopressin Receptor Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .
    Mozavaptan

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: